Jordan’s Hikma Raises Full-Year Forecast As Strong Doxycycline Sales Lift Prospects
This article was originally published in PharmAsia News
Executive Summary
Hikma Pharmaceuticals PLC shrugged off turmoil in its core Middle East markets and reported strong first half sales growth, helping the company to lift full-year revenue growth guidance to around 20% from 13%. The result was lifted by a 10-fold increase in sales of antibiotic doxycycline and continued strong sales in core markets as well as the United States and Europe.
You may also be interested in...
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
A Bright Moment At Last In Turkish Medtech Debt Payments Saga
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.
Turkish Health System Slides Into Crisis After Devaluation Of Lira
Amid delays in surgical operations caused by shortages of equipment and medtech companies demanding payment of outstanding hospital debts, a strong devaluation of the Turkish lira has put the local health care system on a crisis footing.